Pharmaceutical company
Appears in 6 stories
Awaiting the EMA's review outcome; has not yet confirmed submitting its FDA Biologics License Application, previously targeted for 2026
The vaccine, now formally designated PF-07307405 (also called LB6V, and previously known as VLA15), cleared its first regulatory hurdle since March's Phase 3 results. On August 14, 2026, the European Medicines Agency validated Pfizer and Valneva's marketing application, meaning the dossier is complete and formal review can begin.
Updated Aug 15
Developer of oral ritlecitinib for vitiligo
For most of medical history, vitiligo had no fix. Doctors could sometimes slow the spreading white patches, but regrowing lost skin color was mostly out of reach.
Updated Aug 5
Maker of both drugs; sponsor of the FDA application
About one in four men with advanced prostate cancer carry inherited flaws in the genes that repair damaged DNA. A large trial now shows that giving those men a targeted pill alongside standard hormone therapy delays the cancer's spread by a wide margin.
Updated Jul 30
Competitor whose Paxlovid failed as a prevention drug
For years, the only move after a close COVID-19 exposure was to wait and watch for symptoms. Now there is a pill for that.
Updated Jul 29
Co-developer; seeking third-party commercialization partner
For 25 years, drug companies have tried to design medicines that destroy harmful proteins outright rather than blocking them. On May 1, the U.S. Food and Drug Administration (FDA) approved the first one.
Updated May 31
Donating antibiotics through 2030
For the first time since records began, fewer than 100 million people need treatment for trachoma—a bacterial eye disease that's been blinding humans since ancient Egyptian times. The number at risk has cratered 94% since 2002, from 1.5 billion to 97 million. Twenty-seven countries have eliminated it entirely, making trachoma one of the success stories celebrated at World NTD Day 2026 on January 30.
Updated May 20
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
